1[1]Souyri M,Vigon I,Penciolelli JF,et al.A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoieyic progenitors.Cell,1990,63:1137
2[2]Kuter DJ.Thrombopoietin:biology and clinical applications.Oncologist,1996,1:98
3[3]Rasko JE,Basser RL,Boyd J,et al.Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF.Br J Haematol,1997,97:871
4[4]Fanucchi M,Glaspy J,Crowford J,et al.Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.N Engl J Med,1997,336:404
5[5]de Souvage FJ,Carver-Moore K,Louh SM,et al.Physiological regulation of early and late stages of megakaryopoiesis by thrombopoietin.Blood,1995,86:2494
6[6]Harker LA,Hunt P,Marzec UM,et al.Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.Blood,1996,87:1833
7[7]Harker LA,Marzec UM,Hunt P,et al.Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.Blood,1996,88:511
8[8]Harker LA,Marzec UM,Kelly AB,et al.Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppresive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.Blood,1997,89:155
9[9]Vadhan-Raj S,Murray LJ,Bueso-Ramos C,et al.Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.Ann Intern Med,1997,126:673
10[10]Rasser RL,Rasko JE,Clarke K,et al.Randomized,blinded,placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.Blood,1997,89:3118
同被引文献21
1Sarkoee-Adoo CB,Kendall JM,Sridhara R,et al.The relationship between the duration of platelet storage and the development of transfusion reactions[J].Transfusion,1998,38(3):229.
2Blumberg N,Heal JM.Immunomodulation by blood transfusion: an evolving scientific and clinical challenge[J].Am J Med,1996,101(): 299-308.
3Donato H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multiceter trial. Pediatrics, 2000,105(5) :1066
4Vamvakas EC, Strauss RG. Meta-analysis of controlled clinical trials studying the efficacy of recombinant human erythroppoietin in reducing blood transfusion in the anemia of prematurity.Transfusion, 2001, 41(4) :406
5Wardle SP, Garr R, Yoxall CW, et al. A pilot randomised contolled trial of peripheral fractional oxygen extraction to guide blood transfusion in preterm infants. Arch Dis Child,2002, 86(1) :F22
6Wang-Rodriguez J, Fry E, Fiehig E, et al. Immune response to blood transfusion in very-low-birthweight infants. Transfusion, 2000, 40(1):25
7Crookston KP, Reiner AP, Cooper LJN, et al. RBC T activation and hemolysis: implicaions for pediatric transfusion management. Transfusion, 2000, 40(7): 801
8Sola MC, Calhoun DA, Hutson AD, et al. Plasma thrombopoietin concentrations in thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol, 1999, 104(1) :90
9Modi N, Carr R. Promising stratagems for reducing the burden of neonatal sepsis. Arch Dis Child, 2000, 83(4):523
10Dane C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood,1998, 92(12) :3218
